Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptinyx Cashes In Post-Naurex Cache With $65m Series A

Executive Summary

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.

Advertisement

Related Content

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Naurex Spinout Aptinyx Launches After Allergan Deal
Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva
Naurex leads VC funding surge with $80 Series C

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel